Agouron starts phase III protease inhibitor studies.
D000293:Adolescent; D000328:Adult; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019259:Lamivudine; D010919:Placebos; D016047:Zalcitabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D010919:Placebos; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine